Line 3: | Line 3: | ||
<head> | <head> | ||
<title>ASIJ_Tokyo</title> | <title>ASIJ_Tokyo</title> | ||
− | |||
<style type="text/css"> | <style type="text/css"> |
Revision as of 11:16, 12 October 2018
A1-AT |
|
Using Stem Cell and CRISPR Technology to Combat Alpha-1 Antitrypsin Deficiency |